Eli Lilly (LLY +3.55%), as a pharmaceutical stock, may be seen as a source of safety for investors — patients need their medicines, and this provides a certain level of revenue stability regardless of the economic backdrop. But in recent times, this company has also become a growth player thanks to its leadership in a space generating high demand: the weight loss drug market.

Lilly, the seller of blockbuster GLP-1 drugs, has seen revenue take off, and that has prompted both cautious and more aggressive investors to pile into the stock. The company has seen its stock advance more than 300% over five years, and in recent months, it reached record levels, trading above $1,200.

Today, with a stock price of more than $1,160, could a stock…